Beyond Air (NASDAQ:XAIR) issued its quarterly earnings data on Wednesday. The company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.07, Fidelity Earnings reports.
Shares of XAIR stock opened at $5.25 on Friday. The company’s 50-day moving average price is $5.32. Beyond Air has a fifty-two week low of $4.62 and a fifty-two week high of $7.96. The company has a market capitalization of $107.56 million, a PE ratio of -3.78 and a beta of -0.57. The company has a debt-to-equity ratio of 0.26, a current ratio of 7.99 and a quick ratio of 7.99.
A number of research analysts recently commented on XAIR shares. Truist Securities started coverage on Beyond Air in a research note on Wednesday, April 28th. They set a “buy” rating and a $12.00 price objective for the company. Zacks Investment Research upgraded Beyond Air from a “sell” rating to a “hold” rating in a research note on Wednesday, April 14th. Finally, Truist started coverage on Beyond Air in a research note on Wednesday, April 28th. They set a “buy” rating and a $12.00 price objective for the company.
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc and changed its name to Beyond Air, Inc in June 2019.
Recommended Story: What is a Candlestick Chart?
Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.